These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16314887)

  • 21. Current therapies and new strategies for the management of Alzheimer's disease.
    Aderinwale OG; Ernst HW; Mousa SA
    Am J Alzheimers Dis Other Demen; 2010 Aug; 25(5):414-24. PubMed ID: 20601643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons.
    Wang DC; Chen SS; Lee YC; Chen TJ
    Neurosci Lett; 2006 May; 398(1-2):78-82. PubMed ID: 16412575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid beta up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid beta-related neuritic degeneration.
    Kimura N; Takahashi M; Tashiro T; Terao K
    J Neurosci Res; 2006 Sep; 84(4):782-9. PubMed ID: 16862545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into brain BDNF function in normal aging and Alzheimer disease.
    Tapia-Arancibia L; Aliaga E; Silhol M; Arancibia S
    Brain Res Rev; 2008 Nov; 59(1):201-20. PubMed ID: 18708092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of association between the BDNF gene Val66Met polymorphism and Alzheimer disease in a Chinese Han population.
    He XM; Zhang ZX; Zhang JW; Zhou YT; Tang MN; Wu CB; Hong Z
    Neuropsychobiology; 2007; 55(3-4):151-5. PubMed ID: 17657167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-dependent time course of cerebral brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 in APP23 transgenic mice.
    Schulte-Herbrüggen O; Eckart S; Deicke U; Kühl A; Otten U; Danker-Hopfe H; Abramowski D; Staufenbiel M; Hellweg R
    J Neurosci Res; 2008 Sep; 86(12):2774-83. PubMed ID: 18438945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
    Maczurek A; Hager K; Kenklies M; Sharman M; Martins R; Engel J; Carlson DA; Münch G
    Adv Drug Deliv Rev; 2008; 60(13-14):1463-70. PubMed ID: 18655815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain-derived neurotrophic factor, stress and depression: a minireview.
    Yuluğ B; Ozan E; Gönül AS; Kilic E
    Brain Res Bull; 2009 Mar; 78(6):267-9. PubMed ID: 19111910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview.
    Lebrun B; Bariohay B; Moyse E; Jean A
    Auton Neurosci; 2006 Jun; 126-127():30-8. PubMed ID: 16632412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition.
    Wu A; Ying Z; Gomez-Pinilla F
    Exp Neurol; 2006 Feb; 197(2):309-17. PubMed ID: 16364299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease.
    Francis PT
    Neurodegener Dis; 2008; 5(3-4):241-3. PubMed ID: 18322401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease.
    Wolf SA; Kronenberg G; Lehmann K; Blankenship A; Overall R; Staufenbiel M; Kempermann G
    Biol Psychiatry; 2006 Dec; 60(12):1314-23. PubMed ID: 16806094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment.
    Tsai SJ
    Med Hypotheses; 2007; 68(2):410-4. PubMed ID: 16824691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the CREB pathway for memory enhancers.
    Tully T; Bourtchouladze R; Scott R; Tallman J
    Nat Rev Drug Discov; 2003 Apr; 2(4):267-77. PubMed ID: 12669026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The brain as a target for inflammatory processes and neuroprotective strategies.
    Skaper SD
    Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms mediating pathological plasticity in Huntington's disease and Alzheimer's disease.
    Spires TL; Hannan AJ
    J Neurochem; 2007 Feb; 100(4):874-82. PubMed ID: 17217424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it time to reassess the BDNF hypothesis of depression?
    Groves JO
    Mol Psychiatry; 2007 Dec; 12(12):1079-88. PubMed ID: 17700574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.